Arvinas, Pfizer Secure Exclusive Global License for Rigel’s VEPPANU PROTAC
ARVN•Rigel Pharmaceuticals has granted Arvinas and Pfizer exclusive global rights to its oral PROTAC breast cancer drug VEPPANU (vepdegestrant). The agreement extends Arvinas’s pipeline with a late-stage oncology asset while leveraging Pfizer’s commercial infrastructure.
1. Deal Overview
Rigel Pharmaceuticals has granted Arvinas and Pfizer an exclusive global license to develop and commercialize VEPPANU (vepdegestrant), an oral PROTAC degrader targeting estrogen receptor–positive breast cancer.
2. VEPPANU Profile
VEPPANU is an investigational small-molecule PROTAC designed to induce targeted degradation of the estrogen receptor. Early clinical data have demonstrated favorable safety and proof-of-mechanism, positioning it as a potential late-stage oncology candidate.
3. Strategic Implications
The collaboration bolsters Arvinas’s oncology pipeline by adding a breast cancer asset and capitalizes on Pfizer’s global commercial network. This deal underlines Arvinas’s commitment to PROTAC technology and could accelerate VEPPANU’s market entry pending regulatory approvals.
